Pankaj Kumar Singh (Pankaj K Singh)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 15

Top Venues

Pharmaceutical development and technology

Drug delivery and translational research

TheScientificWorldJournal

Journal of drug targeting

National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India

This page only lists publications with an associated author ORCID identifier.

Affiliation History

National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India Feb 14 2019

India

Research Scientist :: Pharmaceutics

Publications

Mohd Aman Mohd Ateeq, Mayur Aalhate, Srushti Mahajan, Gogikar Shiva Kumar, Sibu Sen, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Amol Dikundwar, Santosh Kumar Guru, Pankaj Kumar Singh
Self-nanoemulsifying drug delivery system (SNEDDS) of docetaxel and carvacrol synergizes the anticancer activity and enables safer toxicity profile: optimization, and in-, ex-vivo and in-vivo pharmacokinetic evaluation. Drug delivery and translational research (2023)
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Santosh Kumar Guru, Pankaj Kumar Singh
Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical development and technology 28 (5) (2023)
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Santosh Kumar Guru, Pankaj Kumar Singh
Chitosan functionalized PCL Nanoparticles Bearing Tyrosine Kinase Inhibitor Osimertinib Mesylate for Effective Lung Cancer Therapy. Pharmaceutical development and technology (2023)
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Santosh Kumar Guru, Pankaj Kumar Singh
Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical development and technology (2023)
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Santosh Kumar Guru, Pankaj Kumar Singh
Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical development and technology 28 (5) (2023)
Mohd Aman Mohd Ateeq, Mayur Aalhate, Srushti Mahajan, Gogikar Shiva Kumar, Sibu Sen, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Amol Dikundwar, Santosh Kumar Guru, Pankaj Kumar Singh
Correction to: Self-nanoemulsifying drug delivery system (SNEDDS) of docetaxel and carvacrol synergizes the anticancer activity and enables safer toxicity profile: optimization, and in-vitro, ex-vivo and in-vivo pharmacokinetic evaluation. Drug delivery and translational research (2023)
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Santosh Kumar Guru, Pankaj Kumar Singh
Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy. Pharmaceutical development and technology 28 (5) (2023)
Mayur Aalhate, Srushti Mahajan, Hoshiyar Singh, Santosh Kumar Guru, Pankaj Kumar Singh
Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer. Drug delivery and translational research (2023)
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Santosh Kumar Guru, Pankaj Kumar Singh
Chitosan functionalized PCL Nanoparticles Bearing Tyrosine Kinase Inhibitor Osimertinib Mesylate for Effective Lung Cancer Therapy. Pharmaceutical development and technology (2023)
Anish Dhuri, Anitha Sriram, Mayur Aalhate, Srushti Mahajan, Kishan Kumar Parida, Hoshiyar Singh, Ujala Gupta, Indrani Maji, Santosh Kumar Guru, Pankaj Kumar Singh
Chitosan functionalized PCL Nanoparticles Bearing Tyrosine Kinase Inhibitor Osimertinib Mesylate for Effective Lung Cancer Therapy. Pharmaceutical development and technology (2023)
Snehal Pardeshi, Amrendra Kumar Tiwari, Uday Titame, Pankaj Kumar Singh, Pavan Kumar Yadav, Manish K Chourasia
Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy. Journal of liposome research 32 (4) (2022)
Deepa Nakmode, Valamla Bhavana, Pradip Thakor, Jitender Madan, Pankaj Kumar Singh, Shashi Bala Singh, Jessica M Rosenholm, Kuldeep Kumar Bansal, Neelesh Kumar Mehra
Fundamental Aspects of Lipid-Based Excipients in Lipid-Based Product Development. Pharmaceutics 14 (4) (2022)
Shashi Chandrama Singh, Muskan Choudhary, Atul Mourya, Dharmendra Kumar Khatri, Pankaj Kumar Singh, Jitender Madan, Harshpal Singh
Acute and Subacute Toxicity Assessment of Andrographolide-2-hydroxypropyl- β -cyclodextrin Complex via Oral and Inhalation Route of Administration in Sprague-Dawley Rats. TheScientificWorldJournal 2022 (2022)
Sheela Modani, Devendrasingh Tomar, Suma Tangirala, Anitha Sriram, Neelesh Kumar Mehra, Rahul Kumar, Dharmendra Kumar Khatri, Pankaj Kumar Singh
An updated review on exosomes: biosynthesis to clinical applications. Journal of drug targeting 29 (9) (2021)
Devendrasingh Tomar, Pankaj Kumar Singh, Sajidul Hoque, Sheela Modani, Anitha Sriram, Rahul Kumar, Jitender Madan, Dharmendra Khatri, Kamal Dua
Amorphous systems for delivery of nutraceuticals: challenges opportunities. Critical reviews in food science and nutrition (2020)

Pankaj Kumar Singh.css-eqlu8i{font-size:small;padding-left:4px;} (Pankaj K Singh)

Publication Activity (10 Years)

Top Topics

Top Venues

Pankaj Kumar Singh (Pankaj K Singh)